News
Cobalis' EU Patent for PreHistin(R) Becomes Effective; Patent Protects Method of Treatment for Cobalis' PreHistin Anti-Allergy Medication
Cobalis Corp. (OTC BB: CLSC), a pharmaceutical development company focused on the treatment of allergy and other atopic conditions, announced today that its Patent No. 1128835, titled "Cyanocobalamin Treatment in Allergic Disease," has been published by the European Patent Office in the European Patent Bulletin 06/25. With its publication today, the patent is now in effect and protects the method of treatment underlying Cobalis' PreHistin(R) anti-allergy medication.
The European patent represents an important extension of Cobalis' patent portfolio consisting of patents issued in the U.S. and Australia and patents pending in Japan, Canada and Mexico. An estimated 36 million people suffer from seasonal allergies in the European countries of France, Germany, Italy, Spain and the United Kingdom.
PreHistin is a sublingual lozenge containing an allergy-opposing amount of Cyanocobalamin that is absorbed through the buccal membrane, allowing direct introduction into the bloodstream. It is believed that PreHistin may reduce the release of symptom causing histamine and other allergic inflammatory mediators into the body. PreHistin potentially offers an alternative to anti-histamines, which generally are taken after the onset of symptoms and can be sedating or have undesirable side affects.